Aurobindo Pharma to receive USFDA approval for Diclofenac Sodium Topical Solution
Aurobindo Pharma announced that its step-down subsidiary company, Aurolife Pharma LLC., has received final FDA approval to manufacture and market Diclofenac Sodium Topical Solution USP, 2% w/w, which is bioequivalent and therapeutically equivalent to Horizon Therapeutics Ireland DAC’s reference listed drug (RLD), Pennsaid Topical Solution, 2% w/w (Horizon). The product is scheduled to be released